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Objective. We assessed characteristics of healing, over time, of two types of expanded polytetrafluoroethylene grafts.
Study design. An experimental histological study in dogs.
Methods. The graft types studied had the same internal diameter (5 mm) but different internodal distances. In one, the
internodal distance was 60 mm in the external surface and 20 mm in the luminal surface. In the other, the internodal distance
was 30 mm throughout the material. Sixteen grafts of each type were implanted between the femoral artery and vein in 16
dogs; explanted 1, 2, 4 or 12 weeks later; and examined histologically.
Results. In both graft types, infiltrating-cell density and maximum cell-penetration depth increased significantly between 1
and 2 weeks after implantation, but no significant increases occurred after 2 weeks. The number of inflammatory cells peaked
1 week after implantation and decreased significantly by 2 weeks. Subsequently, there were no significant changes in
inflammatory cell numbers, suggesting that the inflammatory phase was over by 2 weeks after implantation and the grafts
had become attached to surrounding tissue. There were no significant differences between the two graft types in cell density,
cell-penetration depth, or number of inflammatory cells at any assessment time.
Conclusion. Our results provide histologic support for guidelines recommending that synthetic vascular grafts for
hemodialysis access should not be cannulated until 2 weeks after implantation. Since increasing the internodal distance to
60 mm in the external surface had no effect on graft healing, methods other than manipulation of internodal distance should
be used in developing a graft suitable for early cannulation.
More than 240,000 patients in the United States1 and
about 200,000 in Japan2 receive maintenance hemo-
dialysis therapy for end-stage renal disease. For
vascular access for dialysis, autogenous arteriovenous
(AV) fistulae provide higher patency and lower
complication rates than synthetic vascular access
grafts.3 – 7 However, synthetic grafts must be used in
patients without adequate vessels for creation of
autogenous AV fistulas. In fact, in the United States,
only about 27 or 28% of patients undergoing hemo-
dialysis therapy have functioning autogenous fistulas,
whereas more than 40% have synthetic vascular grafts
implanted.1 Pisoni et al.8 reported that synthetic grafts
were used in 58% of prevalent and incident hemo-
dialysis patients.
Since 1973, when Matsumoto et al.9 first reported
that expanded polytetrafluoroethylene (ePTFE) grafts
employed for arterial reconstruction in dogs had
excellent patency, these grafts have become widely
used for replacement of small and medium vessels
and in bypass procedures. At present, ePTFE is the
most common material for vascular access synthetic
grafts. Usually, when ePTFE grafts are used for
vascular access for hemodialysis, they are not cannu-
lated until after a 2-week graft healing period
following implantation. Therefore, temporary place-
ment of a central venous catheter is often necessary in
patients who must undergo hemodialysis during this
period. However, use of such a catheter may result in
central vein stenosis or occlusion, and it also increases
the risk of failure of a vascular access subsequently
placed in the same limb in which the catheter was
inserted.10 – 13 If an ePTFE graft could be safely
cannulated soon after implantation, placement of a
central venous catheter and its associated compli-
cations could be avoided. Therefore, many attempts
have been made to develop an ePTFE graft with a
short graft maturation period, and several of these
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efforts have involved changing the internodal distance
in the ePTFE material.14 – 20
Although early cannulation of synthetic vascular
access grafts has been practiced in some series,21 – 24
this is associated with several adverse effects, includ-
ing hematoma, seroma, graft laceration, rapid throm-
bosis, and infection. The Dialysis Outcomes Quality
Initiative (DOQI) Clinical Practice Guidelines for
Vascular Access of the National Kidney Foundation
recommend that ePTFE grafts should not be cannu-
lated until 2 weeks after implantation.25 However, this
recommendation appears to be based on opinion
rather than strong evidence.
One method that has been used in attempts to
develop a graft that can be cannulated early is
manipulation of the distance between the nodes in
the ePTFE material of which grafts are constructed (the
graft’s ‘porosity’). We here describe an experimental
study in dogs that investigated whether a longer
internodal distance in ePTFE grafts confers improved
graft healing (or ‘maturation’) over time. We com-
pared two types of commercially availale ePTFE
grafts. One type was a standard graft with a 20–
30 mm internodal distance. The other one was a high
porosity graft, which has a 20 mm internodal distance
in the luminal surface but a 60 mm internodal distance
in the external surface. The outcome measures
assessed were the quantity of cells infiltrating the
graft interstices, the maximum cell-penetration depth,
and the presence of inflammatory cells. Our investi-
gation was designed to provide histological data
relevant to the appropriate waiting period before




Sixteen 10–12-kg mongrel dogs of either sex were used
in this study. All study procedures were reviewed and
approved by the Institutional Animal Care and Use
Committee of Nagoya University Graduate School of
Medicine and were in accordance with the Guide for the
Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council. Washington, DC:
National Academy Press, 1996). Dogs were con-
ditioned to their environment for at least 3 weeks
before studies began and animal health was monitored
by the institutional veterinarian.
The two types of ePTFE grafts studied had the same
internal diameter (5 mm), wall thickness (600 mm),
and nominal length (15 cm), but different internodal
distances. In the type A graft (Hybrid PTFE Graft;
Atrium Medical Corp, Hudson, NH), a high-porosity
graft, the internodal distance in the luminal surface
was 20 mm, whereas that in the external surface was
60 mm. In the type B graft (Impra; Impra, Inc, Tempe,
AZ), the standard graft, the internodal distance was
30 mm throughout the material. Before implantation,
all grafts were cold-gas sterilized by using ethylene
oxide.
Operative technique
After an overnight fast, dogs were given ketamine
chloride (5 mg/kg) intramuscularly and anesthetized
by intravenous administration of thiopental sodium
(10–15 mg/kg). Endotracheal intubation was accom-
plished. Anesthesia was maintained with 1–1.5%
halothane mixed with oxygen, and mechanical venti-
lation was used. During the surgical procedure, blood
volume was supplemented with lactated Ringer’s
solution (20 mL/kg of body weight per hour, not
exceeding 1000 mL). Cefazolin sodium (500 mg) was
given intravenously before the initial incision was
made. Heparin sodium (100 IU/kg) was administered
intravenously 5 min before vascular clamping. A
single additional dose of heparin (50 IU/kg) was
given 1.5 hours later if graft anastomoses were still
incomplete. Protamine sulfate (1 mg/90 U residual
heparin) was used to reverse the effect of heparin.
After sterile preparation, a 5-cm groin incision was
made to expose the common femoral artery and vein. A
subcutaneous ‘U’ tunnel was created distally down the
medial portion of the thigh. One type of graft was
anastomosed in an acute-angle, end-to-side fashion first
to the femoral artery by using continuous 6–0 poly-
propylene sutures and then to the ipsilateral common
femoral vein. The other type of graft was then implanted
between the contralateral femoral artery and vein by
using the same methods. For each dog, the side for graft
implantation was determined randomly.
Graft harvest and histologic studies
Each graft type was harvested from four dogs at 1, 2, 4
and 12 weeks after implantation. For graft harvest, the
dogs were anesthetized and heparin (100 IU/kg) was
administered intravenously. Grafts were dissected
carefully with the tissue capsule around them intact.
The dogs were then killed with an intravenous
overdose of thiopental sodium.
Explanted grafts were fixed in 10% phosphate-
buffered formalin. Specimens were obtained from two
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sites 5 cm away from each anastomosis in each graft
and embedded in paraffin. Longitudinal sections
(5 mm thick) were prepared and stained with hema-
toxylin and eosin (H and E). To identify inflammatory
cells, immunohistochemical staining using CD45RO
monoclonal antibody (clone UCHL1, isotype, IgG2a;
Serotec Ltd, Oxford, United Kingdom) was performed
after deparaffinization. The histological sections were
examined by a pathologist blinded to the graft type
and implant duration. The quantity of cells and
maximum cell-penetration depth in the graft inter-
stices were measured in three different fields for
each specimen (50 £ magnification). Inflammatory
(CD45ROþ) cells were counted in each specimen
stained with the monoclonal antibody (50 £
magnification).
Statistical analysis
Data were expressed as means ^ SD. Differences
between variables were assessed by using analysis of
variance or Mann–Whitney U test. A P value of less
than 0.05 was considered to be significant. All
statistical analyses were performed using Statview
software (Abacus Concepts, Inc, Berkeley, CA).
Results
Results are shown in Table 1 and Figs. 1 and 2. For
both graft types, cell quantity and maximum cell-
penetration depth increased significantly (ANOVA)
between 1 and 2 weeks after implantation, but no
additional significant increases (ANOVA) were
observed after 2 weeks. There were no significant
differences (Mann–Whitney U test) between the graft
types in either of these variables at any time interval
studied. Infiltration of inflammatory cells into graft
interstices peaked 1 week after implantation in both
types of grafts. The number of interstitial inflammatory
cells decreased significantly (ANOVA) 2 weeks after
implantation, and no significant increases (ANOVA)
were observed at later time intervals. There were no
significant differences, between the graft types, in the
number of inflammatory cells at any time interval
(Mann–Whitney U test).
Discussion
We evaluated, in an experimental study in dogs,
aspects of graft healing in two ePTFE grafts with
different internodal distances, a high-porosity graft
(i.e., one with longer internodal distances) and a
standard graft. We found that connective tissue
ingrowth into the interstices of both grafts increased
significantly between the first and second week after
implantation. In addition, infiltration of inflammatory
cells into the interstices of both grafts peaked 1 week
after implantation and decreased markedly by 2
weeks. These results indicate that the inflammatory
process had ended and fibroblast proliferation was
almost complete by 2 weeks after implantation. The
external surfaces of the grafts were firmly attached to
the surrounding tissue with collagen fibers by this
time. These histological observations support the idea
that ePTFE grafts have matured sufficiently by 2 weeks
after implantation to allow safe cannulation for
dialysis, but that healing is incomplete before this
time. Thus the findings provide histological support
for The Dialysis Outcomes Quality Initiative (DOQI)
Clinical Practice Guidelines.25
All synthetic vascular grafts, regardless of their
composition, are porous, and porosity has been found
Table 1. Histologic findings in the two graft types at various times after implantation
Histologic variable/graft type* Weeks after implantation
1 2 4 12
Mean ^ SD no. of cells in graft interstices (£102 cells/mm2)
Type A 2.4 ^ 2.3 7.5 ^ 4.0† 9.2 ^ 4.5 9.4 ^ 5.2
Type B 2.6 ^ 2.8 8.2 ^ 2.9† 7.2 ^ 6.0 9.5 ^ 6.9
Mean ^ SD maximum depth of penetration of cells into graft interstices (£102 mm)
Type A 1.2 ^ 1.3 3.7 ^ 1.2† 4.1 ^ 1.7 5.7 ^ 0.8
Type B 0.8 ^ 0.9 4.0 ^ 1.6† 3.3 ^ 2.4 5.1 ^ 1.3
Mean ^ SD no. of inflammatory cells in graft interstices (£102 cells/mm2)
Type A 1.9 ^ 0.6 1.1 ^ 0.4† 1.4 ^ 0.6 1.8 ^ 1.0
Type B 2.5 ^ 1.3 1.2 ^ 0.7† 1.2 ^ 0.9 1.3 ^ 0.6
*In type A, the internodal distance in the external surface was 60 mm and that in the luminal surface was 20 mm; in type B, all internodal
distances were 30 mm.
†Significantly different from values obtained 1 week after implantation for each graft type ðP , 0:05Þ: There were no significant differences
between the graft types in any histologic variable at any assessment time and no significant changes in any histologic variable from weeks 2 to
12 for either graft type.
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to be related to graft healing.26 Most attempts to
develop an ePTFE graft that can be cannulated early
have focused on graft porosity.14,27 Stronck et al.15
reported that fibroblasts originating from the perigraft
region began to infiltrate the interstices of ePTFE grafts
with a 60 mm internodal distance by a week after
implantation of the grafts in rats. Other studies also
suggested that ePTFE grafts with longer internodal
distances had decreased thrombogenicity and encour-
aged rapid and extensive ingrowth from surrounding
tissue that resulted in better graft healing.16 – 20
For the current study, we hypothesized that ePTFE
grafts with a longer internodal distance (type A grafts)
would have a shorter healing or maturation period
that might allow earlier clinical cannulation. We
found, however, that tissue ingrowth into the inter-
stices of these grafts was not greater and did not occur
more quickly than that in standard (type B) grafts with
a uniform internodal distance of 30 mm. These find-
ings indicate that the internodal distances, even in the
standard grafts were larger than the size of infiltrating
cells, thereby allowing the cells to enter the material.
Thus, the longer internodal distance in the type A
grafts did not have any advantage with respect to
tissue ingrowth into the interstices of the grafts or graft
maturation. Our study compared internodal distances.
Therefore, we cannot assess whether internodal dis-
tances longer 60 mm than might be beneficial. AV
fistulae for hemodialysis are created in patients with
renal impairment, in the presence of diabetes mellitus
and other co-existing atherosclerotic disease. Such
conditions may have an adverse affect on graft
healing. It is a further limitation of our study that the
dogs did not have chronic renal failure or athero-
sclerotic disease. Therefore, our findings in dogs may
not be translatable to humans with specific conditions.
If manipulating the internodal distance does not
hasten maturation of ePTFE grafts used for vascular
Fig. 1. Light micrograph of type A ePTFE graft obtained 7
days after implantation in a dog. Tissue ingrowth appears in
the interstices in the external surface of the graft (H and E
staining; original magnification £ 50). Inset shows inflam-
matory infiltrates in the middle portion of the graft but no
stromal cells (H and E staining, original magnification £180).
Fig. 2. Light micrograph of type A ePTFE graft obtained 14
days after implantation in a dog. Tissue ingrowth has
advanced from the interstices in the external surface of the
graft to those in the middle portion (H and E staining,
original magnification £ 50). Inset shows stromal cell
growth but only rare inflammatory cells (H and E staining,
original magnification £ 180).
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access for hemodialysis, a shift in the focus of research
aimed at achieving safe early cannulation may be
necessary. The DIASTAT graft, that is designed to
prevent bleeding through the puncture hole and allow
early cannulation, has been developed. This graft
contains a cannulation segment consisting of a stretch
ePTFE base tube surrounded by flat and round ePTFE
fibers that are secured by a thin, perforated ePTFE
cover. However, in this graft, the incidence of early
thrombosis and infection is increased in comparison to
the standard ePTFE grafts.28 Therefore, this graft has
not been widely accepted. Carbon seeding of the
luminal surface in Dacron grafts decreased the
thrombogenicity.29 In ePTFE grafts, however, carbon
seeding of the luminal surface did not improve graft
healing in dogs.19 Miura et al.30 examined, in dogs, the
biological behaviour of two types of ePTFE graft with
the same internodal distance of 60 mm but with
different node-fibril morphology. They concluded
that graft healing, enhanced by tissue ingrowth, was
largely independent of node-fibril morphology.
Nishibe et al.31 investigated the effect of fibronectin
bonding on the healing of ePTFE grafts with an
internodal distance of 60 mm in pigs, and indicated
that fibronectin bonding stimulated transmural tissue
ingrowth in the high porosity grafts.
One promising alternative research area is genetic
and tissue engineering. Studies have demonstrated
that administration of fibroblast growth factor pro-
motes rapid and extensive tissue ingrowth into the
interstices of ePTFE grafts and contributes to improve-
ments in graft healing.32 – 35 Furthermore, tissue-
engineering techniques may be used to create com-
pletely new types of grafts. Fields et al.36 reported that
the electrostatic endothelial cell seeding with the
tissue-engineering technique had a significant impact
on the healing of ePTFE grafts in dogs, and speculated
that this procedure accelerated the acute healing of
ePTFE grafts. In 1986, Weinberg et al.37 described a
tissue-engineered blood vessel developed from col-
lagen gels with bovine endothelial cells, smooth
muscle cells, and fibroblasts. The vessel had poor
mechanical strength, but the methods used to con-
struct it were subsequently employed by many
researchers and, in 1998, L’Heureux et al.38 created a
tissue-engineered human blood vessel with increased
mechanical strength. If it becomes possible to use
tissue-engineering techniques to manufacture made-
to-order blood vessels for clinical applications, the
vessels created should have all the characteristics of
ideal vascular access grafts: nonthrombogenicity,
resistance to infection, biocompatibility, and avail-
ability in many sizes.
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